… The therapy for multiple sclerosis (MS) has changed dramatically over the past decade.
Recent … Since failed trials add to our growing understanding of multiple sclerosis, ‘misses’ are …

… the treatment of multiple sclerosis (MS). However, a remarkable number of mAbs failed due
to … This review summarizes MS mAbs that have either failed in phase II–III trials, have been …

… Energy failure is an emerging concept in multiple sclerosis … with an emphasis on multiple
sclerosis. Combination of these … into the pathophysiology of multiple sclerosis and may provide …

… Multiple sclerosis is a common cause of neurological disability in young adults. The disease
… , and sometimes proceeds to completion in multiple sclerosis. But as the disease progresses…

… symptoms in multiple sclerosis generally fall into the categories of failure to store. failure to …
has a beneficial effect on the outcome of multiple sclerosis. although they appear to be useful …

… The number of pharmacological agents approved for the treatment of multiple sclerosis … fail
to show a benefit. Although preceding animal models or rational pathophysiological concepts …

Multiple sclerosis, an inflammatory disease of the central nervous system, is characterized
by primary destruction of myelin. This review covers recent advances in neuropathology, …

Experimental autoimmune encephalomyelitis (EAE) is often termed “the” model of human
multiple sclerosis (MS). This is, however, an oversimplification. MS is a multifaceted disorder, …

… failed or have been interrupted for various reasons. We identify potential causes of failure or
… Failed or inconclusive multiple sclerosis (MS) trials are invaluable to our understanding of …

… Therapeutic approaches that have previously failed in MS have indicated that there are …
2001 that failed or were interrupted, attempts to analyze the underlying reasons for failure, and …